Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
2021 · New England Journal of Medicine · 828 citations
https://doi.org/10.1056/nejmoa2103485
J
Jean‐François Baurain
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
281
Papers
11.7K
Citations
35
h-index
76
i10-index
Jean‐François Baurain is an academic researcher from Cliniques Universitaires Saint-Luc. The author has contributed to research in topics: Immunotherapy and Immune Responses & Monoclonal and Polyclonal Antibodies Research & Glioma Diagnosis and Treatment. The author has an h-index of 35, co-authored 239 publications.
ORCID: 0000-0003-4876-4600Papers by this author
worksA Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
2011 · Clinical Cancer Research · 104 citations
https://doi.org/10.1158/1078-0432.ccr-11-0070
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial
2022 · Clinical Cancer Research · 69 citations
https://doi.org/10.1158/1078-0432.ccr-21-4283
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
2023 · Annals of Oncology · 36 citations
https://doi.org/10.1016/j.annonc.2023.11.013
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
2023 · Annals of Oncology · 35 citations
https://doi.org/10.1016/j.annonc.2023.10.123
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases
2023 · ESMO Open · 33 citations
https://doi.org/10.1016/j.esmoop.2023.100884
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat